1. Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care

   • Ya-Chen Tina Shih
   • Shelley Fuld Nasso
   • S. Yousuf Zafar

   Editorial 02 February 2018 Pages: 259 - 261

2. Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions

   • Paolo A. Cortesi
   • Lucia S. D’Angiolella
   • Lorenzo G. Mantovani

   Review Article 23 November 2017 Pages: 263 - 284

   

3. Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Bram L. T. Ramaekers
   • Robert Wolff
   • Manuela A. Joore

   Review Article Open access 25 November 2017 Pages: 285 - 288

4. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Nigel Fleeman
   • Ahmed Abdulla
   • Daniel Palmer

   Review Article 24 November 2017 Pages: 289 - 299

5. Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review

   • Lazaros Andronis
   • Ilias Goranitis
   • Rui Duarte

   Systematic Review 09 December 2017 Pages: 301 - 322

   

6. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review

   • Peter Ghijben
   • Yuanyuan Gu
   • Silva Zavarsek

   Systematic Review 09 November 2017 Pages: 323 - 340

   

7. A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis

   • Shijie Ren
   • Jonathan Minton
   • Matt Stevenson

   Original Research Article Open access 28 October 2017 Pages: 341 - 347

   

8. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis

   • Rebekah Fong Soe Khioe
   • Chris Skedgel
   • Leo Alexandre

   Original Research Article 05 December 2017 Pages: 349 - 358

   

9. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

   • Amr Makady
   • Ard van Veelen
   • Wim Goettsch

   Original Research Article Open access 06 December 2017 Pages: 359 - 368

   

10. Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases

    • Margret V. Bjarnadottir
    • David Czerwinski
    • Eberechukwu Onukwugha

    Original Research Article 11 December 2017 Pages: 369 - 380

    

11. Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

    • Amir Ansaripour
    • Carin A. Uyl-de Groot
    • W. Ken Redekop

    Letter to the Editor 09 February 2018 Pages: 381 - 382

    

12. Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

    • Noga Gershon
    • Yakir Berchenko

    Letter to the Editor 13 February 2018 Pages: 383 - 384